• Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) 

      Eide, Inger Johanne; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Brustugun, Odd Terje (Peer reviewed; Journal article, 2020)
      Objectives In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of ...
    • Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016 

      Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond-Eirik; Solberg, Steinar (Journal article; Peer reviewed, 2018)
      Introduction There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are ...